Compare Ginkgo Bioworks Holdings Inc (DNA) vs Zillow Group Inc Class C (Z) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Zillow Group (Z) trades at $28.84, up 5.72% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, turning a net loss of $112M into a $23M profit. Recent earnings show beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Analyst sentiment is divided with a $60.33 consensus price target representing significant upside potential from current levels.

Zillow presents a compelling growth story with improving profitability and strong analyst targets, but faces headwinds from housing market volatility and rising mortgage rates. The stock's high P/E ratio of 126.83 reflects growth expectations, while technical indicators show conflicting signals with bullish overall momentum but bearish moving averages. The resolution of the FTC lawsuit removes regulatory overhang, but competition with Compass and market sensitivity to interest rates remain key risks.